Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'
- PMID: 33962960
- DOI: 10.1136/annrheumdis-2021-220586
Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'
Keywords: COVID-19; autoimmune diseases; vaccination.
Conflict of interest statement
Competing interests: MDC has received speaking fees from AbbVie and Novartis. FS has received speaking fees from Roche, AbbVie, Novartis, Bristol-Myers-Squibb, Pfizer and Merck Sharp and Dohme Italia. EF has received speaking fees from AbbVie, BMS, Janssen, Lilly, MSD, Novartis, Roche, Pfizer and UCB Pharma. WG has received speaking fees from AbbVie, Celgene, Grünenthal, Pfizer and UCB Pharma. All other authors disclose no conflict of interest.
Comment in
-
Response to: 'Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'' by Smerilli et al.Ann Rheum Dis. 2021 Oct;80(10):e169. doi: 10.1136/annrheumdis-2021-220612. Epub 2021 May 7. Ann Rheum Dis. 2021. PMID: 33962963 No abstract available.
Comment on
-
SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists.Ann Rheum Dis. 2021 Jul;80(7):953-954. doi: 10.1136/annrheumdis-2021-220059. Epub 2021 Feb 23. Ann Rheum Dis. 2021. PMID: 33622689 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
